- Conditions
- Allergic Fungal Rhinosinusitis
- Interventions
- Dupilumab, Placebo, Intranasal Corticosteroid Sprays (INCS)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 171
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prurigo Nodularis
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Fremont, California • Laguna Hills, California + 18 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Dupilumab SAR231893, Placebo, non sedating H1-antihistamine
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Years to 80 Years
- Enrollment
- 397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Sarasota, Florida • Sweetwater, Florida + 13 more
- Conditions
- Asthma
- Interventions
- Dupilumab, Placebo (for Dupilumab), Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy, Albuterol, Levalbuterol
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 50
- States / cities
- Anaheim, California • Long Beach, California • Los Angeles, California + 42 more
- Conditions
- Atopic Dermatitis
- Interventions
- Apremilast
- Drug
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Atopic Keratoconjunctivitis
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- Andover Eye Associates
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Littleton, Colorado • Hollywood, Florida + 17 more
- Conditions
- Cold Urticaria
- Interventions
- Dupilumab SAR231893, Placebo, Non sedating H1-antihistamine
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 5
- States / cities
- San Diego, California • Boise, Idaho • Owensboro, Kentucky + 2 more
- Conditions
- Aspirin-exacerbated Respiratory Disease
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- Rochester General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Atopic Dermatitis, Eczema
- Interventions
- Dupilumab Prefilled Syringe
- Biological
- Lead sponsor
- Jonathan A. Bernstein, MD
- Other
- Eligibility
- 19 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Eosinophilic Disorder, Food Allergy
- Interventions
- Entero-tracker, omalizumab, dupliumab
- Device · Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 5 Years to 55 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Dermatitis, Atopic
- Interventions
- Dupilumab, Placebo (for Dupilumab)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 708 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 53
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 50 more
- Conditions
- Atopic Dermatitis (AD), Asthma
- Interventions
- dupilumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 581 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Atopic Dermatitis
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 880 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 35 more
- Conditions
- Asthma
- Interventions
- SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination, Placebo for SAR440340, Placebo for dupilumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more
- Conditions
- Asthma
- Interventions
- Dupilumab, Placebo, Oral corticosteroid therapy (prednisone/prednisolone), Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Rolling Hills Estates, California • St Louis, Missouri + 4 more
- Conditions
- Dermal Hypersensitivity Reaction
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 9
- States / cities
- Coral Gables, Florida • Boise, Idaho • St Louis, Missouri + 6 more
- Conditions
- Prurigo Nodularis
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 15
- States / cities
- Palo Alto, California • Rancho Santa Margarita, California • Walnut Creek, California + 12 more
- Conditions
- Eosinophilic Esophagitis (EoE)
- Interventions
- Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT], budesonide oral suspension
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Atopic Dermatitis and Related Conditions
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Dupilumab, Fluticasone
- Biological · Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 12 Years to 25 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Asthma
- Interventions
- SAR231893, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 12
- States / cities
- Bakersfield, California • Culver City, California • Los Angeles, California + 9 more
- Conditions
- Atopic Dermatitis
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 22 more